Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $8.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective lifted by UBS Group from $7.00 to $8.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. BTIG Research reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. B. Riley Financial reduced their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday. Truist Financial set a $12.00 price target on Perspective Therapeutics in a report on Tuesday. Finally, Royal Bank Of Canada reduced their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Stock Performance

NYSEAMERICAN:CATX opened at $4.45 on Wednesday. The business has a 50 day simple moving average of $4.37 and a 200 day simple moving average of $3.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 5.17. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The company had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. On average, equities analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new position in Perspective Therapeutics during the second quarter valued at about $61,000. Geode Capital Management LLC grew its holdings in shares of Perspective Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after purchasing an additional 405,612 shares in the last quarter. Walleye Capital LLC increased its position in shares of Perspective Therapeutics by 375.8% during the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares during the period. Finally, Federated Hermes Inc. increased its position in shares of Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after purchasing an additional 60,019 shares during the period. 54.66% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Perspective Therapeutics

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: UBS raised its price target for CATX to $8.00, signaling increased upside from current levels and giving investors a higher valuation reference. UBS Group Raises Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $8.00
• Positive Sentiment: B. Riley Financial analyst says CATX stock price is expected to rise, which can attract momentum buying and support higher valuations. Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Expected to Rise, B. Riley Financial Analyst Says
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on CATX, reinforcing buy-side sentiment from another boutique/specialist analyst. Wedbush Reaffirms “Outperform” Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)
• Positive Sentiment: Brookline Capital Markets materially raised its FY2026 and quarter-by-quarter EPS estimates (still negative EPS, but less severe), suggesting improving expectations for the company’s financial trajectory. This reduces downside risk from prior forecasts. (Market data / analyst note)
• Positive Sentiment: BTIG initiated/maintained a Buy rating on CATX, adding further institutional buy-side support. Perspective Therapeutics (NYSEAMERICAN:CATX) Earns Buy Rating from BTIG Research
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX, which can add short-term pressure and offset some of the positive analyst actions. Royal Bank Of Canada Has Lowered Expectations for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.